Celldex Therapeutics (NASDAQ:CLDX) Earns “Buy” Rating from Stifel Nicolaus

Celldex Therapeutics (NASDAQ:CLDX)‘s stock had its “buy” rating restated by stock analysts at Stifel Nicolaus in a research report issued on Thursday,Benzinga reports. They currently have a $68.00 price objective on the biopharmaceutical company’s stock, up from their previous price objective of $58.00. Stifel Nicolaus’ price objective would indicate a potential upside of 125.99% from the stock’s current price.

A number of other equities analysts have also weighed in on CLDX. Barclays upped their target price on Celldex Therapeutics from $21.00 to $24.00 and gave the stock an “underweight” rating in a research report on Wednesday, December 17th. Weiss Ratings restated a “sell (d-)” rating on shares of Celldex Therapeutics in a report on Wednesday, January 21st. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has issued a Hold rating and two have given a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $44.20.

Celldex Therapeutics Trading Down 1.8%

Shares of NASDAQ CLDX opened at $30.09 on Thursday. The firm has a market capitalization of $2.00 billion, a P/E ratio of -7.74 and a beta of 1.24. The firm’s 50-day moving average price is $25.70 and its 200-day moving average price is $25.50. Celldex Therapeutics has a 1-year low of $14.40 and a 1-year high of $31.31.

Celldex Therapeutics (NASDAQ:CLDX) last issued its earnings results on Wednesday, February 25th. The biopharmaceutical company reported ($1.22) EPS for the quarter, missing analysts’ consensus estimates of ($1.00) by ($0.22). Celldex Therapeutics had a negative net margin of 3,446.88% and a negative return on equity of 39.67%. The firm had revenue of $0.12 million during the quarter, compared to the consensus estimate of $1.53 million. Equities research analysts forecast that Celldex Therapeutics will post -2.48 EPS for the current year.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the company. Handelsbanken Fonder AB boosted its holdings in Celldex Therapeutics by 2.4% during the second quarter. Handelsbanken Fonder AB now owns 21,600 shares of the biopharmaceutical company’s stock worth $440,000 after purchasing an additional 500 shares during the last quarter. Russell Investments Group Ltd. boosted its stake in shares of Celldex Therapeutics by 27.6% in the 2nd quarter. Russell Investments Group Ltd. now owns 2,315 shares of the biopharmaceutical company’s stock worth $47,000 after buying an additional 501 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in shares of Celldex Therapeutics by 1.6% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 43,451 shares of the biopharmaceutical company’s stock worth $798,000 after buying an additional 680 shares during the last quarter. ProShare Advisors LLC grew its holdings in shares of Celldex Therapeutics by 6.9% in the fourth quarter. ProShare Advisors LLC now owns 11,973 shares of the biopharmaceutical company’s stock valued at $325,000 after acquiring an additional 773 shares in the last quarter. Finally, AlphaQuest LLC increased its position in shares of Celldex Therapeutics by 7.0% during the second quarter. AlphaQuest LLC now owns 12,956 shares of the biopharmaceutical company’s stock valued at $264,000 after acquiring an additional 844 shares during the last quarter.

Key Headlines Impacting Celldex Therapeutics

Here are the key news stories impacting Celldex Therapeutics this week:

• Positive Sentiment: New Phase 2 clinical data for barzolvolimab presented at AAAAI show sustained off‑treatment efficacy in chronic spontaneous urticaria (CSU) and meaningful quality‑of‑life gains in cold urticaria/symptomatic dermographism — potential upside for future regulatory/label discussions and commercial prospects. Celldex Presents Additional Positive Data
• Positive Sentiment: Analyst bullishness: Stifel reaffirmed a Buy and raised its price target to $68, and Morgan Stanley reiterated a Buy — these upgrades/support increase the stock’s upside narrative for investors focused on clinical catalysts. Stifel Reaffirms Buy, Raises PT
• Positive Sentiment: Sell‑side coverage remains constructive overall (average rating around “Moderate Buy”), which can sustain interest into upcoming 2026 data readouts and EMBARQ enrollment updates. TipRanks / Analyst Note
• Neutral Sentiment: HC Wainwright published EPS forecasts for FY2026/FY2027 (negative EPS expected), providing modeling detail but no change in clinical outlook; useful for valuation but not an immediate catalyst. HC Wainwright Estimates (MarketBeat)
• Neutral Sentiment: Mixed media and analyst commentary (Beaumont Enterprise, AmericanBankingNews) reinforce analyst interest but do not add new clinical or financial surprises. Q4 Snapshot
• Negative Sentiment: Recent Q4 2025 financials disappointed: the company missed EPS and revenue expectations, reported very large negative margins and negative ROE, and consensus still expects meaningful losses for 2026 — headwinds for near‑term sentiment and valuation. Q4 and Year‑End 2025 Results
• Negative Sentiment: Short interest data posted recently are inconsistent/odd (reported as zero), which may create temporary noise but reflects no clear short‑pressure signal.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted immunotherapies for cancer and other serious diseases. The company’s research platforms leverage novel antibody and vaccine technologies designed to engage the patient’s immune system, with a particular emphasis on oncology and neurologic indications. Celldex’s pipeline includes both monoclonal antibodies and biologic agents that seek to modulate immune responses or deliver targeted cytotoxic activity.

Among Celldex’s lead product candidates is glembatumumab vedotin, an antibody–drug conjugate directed against the glycoprotein NMB (gpNMB) for the treatment of certain breast and skin cancers.